NNHPD Regulatory Tools Update: How New Guidance Improves NHP and Non-Prescription Drug Submissions

Health Canada Compliance Natural Health Products
November 24, 2025

Health Canada’s Natural and Non-prescription Health Products Directorate (NNHPD) has released two major regulatory tools — the Monograph Combination Guide and the List of Interchangeable Terms. These updates are designed to streamline submissions, enhance clarity, and improve labelling flexibility for Natural Health Products (NHPs) and non-prescription drugs entering the Canadian market.

1. Monograph Combination Guide: What It Means for Applicants

The Monograph Combination Guide helps companies understand how multiple NNHPD monographs can be applied within a single product formula. This improves predictability for applicants and reduces the chance of unexpected review escalations.

Key Enhancements

Clear rules for compatibility between monographs
How to evaluate shared warnings, cautions, and contraindications
Requirements for additive dosing of ingredients with similar pharmacological actions
Guidance on qualifying for Class I (monograph-based) submissions
Triggers that automatically move products into Class II or Class III review

Specific Qualifiers

The guide introduces specific qualifiers, which are statements that contextualize certain claims. When combining monographs, companies must ensure that the qualifiers remain accurate and are not contradicted by the other ingredients in the formulation.

Managing Conflicting Conditions

If formula ingredients create:

contradictory claims,
opposing therapeutic actions,
or incompatible conditions of use,
the product will not qualify for Class I or II. These cases require Class III submissions with full supporting evidence.

Additive Dosing Requirements

For ingredients with similar therapeutic actions such as:

stimulant laxatives
diuretics
hypoglycemic agents
blood-pressure modulating herbs

NNHPD expects cumulative dose calculations. If combined doses exceed monograph limits, the product must follow a higher-level submission pathway.

Special Rules for Proteins and Amino Acids

The framework provides detailed requirements including:

differentiation between complete proteins and free amino acids
adherence to minimum and maximum content limits
evidence-based support for amino acid combinations

The 10% Sub-Therapeutic Rule

Ingredients present at less than 10% of their monograph dosage cannot contribute to claims, directions, or conditions of use. This ensures that label claims are truthful and accurately supported.

2. List of Interchangeable Terms: Greater Label Flexibility

The List of Interchangeable Terms allows companies to use alternative label expressions without impacting compliance, provided the meaning remains equivalent.

Benefits for Companies

Greater creative freedom in branding and design
Lower risk of review-stage label changes
Improved consumer clarity
Better consistency across multi-SKU product lines in both English and French

Examples of Practical Use

This tool is especially beneficial for:

Multi-monograph bone and joint formulations
Herbal combinations like turmeric–ginger–cinnamon
OTC-aligned NHPs needing standardized terminology
Protein or amino-acid blends with multiple monograph sources

Recommended Next Steps for Manufacturers

To leverage these changes, companies should:

Review existing formulas for monograph alignment
Apply interchangeable terminology to optimize labels
Update internal SOPs and regulatory review workflows
Train regulatory staff on monograph qualifiers and conflict evaluation
Identify products that can now transition to Class I submissions

Impact on Submission Strategy

These changes may significantly reduce time-to-market. Products that previously required Class II review may now qualify for Class I under the updated combination rules, reducing approval timelines from months to weeks.

Looking Ahead

NNHPD continues to modernize its regulatory framework. Companies can expect: